The department of PKDM within Amgen is dedicated to the discovery and development of safe and effective medicines by elucidating the absorption, distribution, metabolism, excretion and pharmacokinetic properties of novel therapeutic drug candidates to improve their pharmacological potential. PKDM works in close partnership with disciplines such as protein science, pharmacology, toxicology, pharmaceutical sciences, clinical pharmacology and regulatory to engineer promising clinical therapeutic candidates, conduct preclinical development studies, support clinical evaluation and contribute to IND and NDA filings.
Develop and routinely employ bioanalytical methods for the quantitative and qualitative analysis of new protein/mAb entities in plasma, tissues, and other biological matrices, as well as, interpret and provide bioanalytical results to project team representatives in support of drug discovery and development.
Design and execute experiments to quantitate molecular entities by immunoassay (ELISA, Gyros, MSD) in support of both drug discovery and early development programs.
Understand preclinical ADME and bioanalytical techniques and work collaboratively in a fast-paced work environment.
Work as a member of the bioanalytical group and responsible for sample preparation, tissue homogenization, affinity capture, data generation and analysis with Watson-LIMS.
Assist in troubleshooting when instrument or assay problems arise.
Basic bioanalytical research, electronic laboratory notebook keeping and communication of results to project teams.
Master's degree and 3 years of scientific experience
Bachelor's degree and 5 years of scientific experience
MS or BS in biology, chemistry, biochemistry, immunology or equivalent.
Experience with independent operation of various automated immunoassay platforms.
Excellent oral and written communication skills.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.